Existing pre-approved FDA drugs targeting potassium channels may help in Cancer treatment Electrical voltage patterns in healthy cells serve as a guide for a well-organized cell development process. The opposite occurs with cancer, though. Cells lose their specialized roles, start growing into tumors, and spread into other tissues-a process known as metastasis. This process also causes a breakdown in the cell's normal electrical patterns. Metastasis continues to be the biggest cause of death in cancer patients, and drugs that modulate the electrical patterns of tumor cells may hold promise as novel treatments. Researchers at Tufts University recently demonstrated that tumor cell invasion in vitro and metastasis in animal models of breast cancer can both be reduced considerably by altering the voltage patterns in tumor cells using ion channel blocking drugs that have already received FDA approval for the treatment of other illnesses.
Fluxion is a California-based company that develops products such as liquid biopsy systems and cellular analysis tools for drug discovery and diagnostic applications.